EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Yi-Ting Chen, Tzu-I Chen, Szu-Ching Yin, Chia-Wei Huang, Jee-Fu Huang iD, Sheng-Nan Lu iD, Ming-Lun Yeh iD, Chung-Feng Huang iD, Chia-Yen Dai iD, Yu-Wei Chen, Wan-Long Chuang, Ming-Lung Yu iD und 1 weitere

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Yi-Ting Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Cardiovascular Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taipei, Taiwan, NYCU-KMU Joint Research Project, Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim This study estimated the prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) according to cardiometabolic risk factors. The long‐term impacts of MASLD on all‐cause and cardiometabolic‐specific mortality were evaluated.

Methods

We enrolled 343 816 adults aged ≥30 years who participated in a health screening program from 1997 through 2013. MASLD was identified on the basis of abdominal ultrasonography and metabolic profiles. The participants were further categorized by liver enzyme elevation. Baseline cardiometabolic comorbidities were classified on the basis of self‐reported medication use and clinical seromarkers. All‐cause and cardiometabolic‐specific deaths were determined through computerized data linkage with nationwide death certifications until December 31, 2020.

Results

The overall prevalence of MASLD was 36.4%. Among patients with MASLD, 35.9% had abnormal liver enzyme levels. Compared with patients without MASLD, abnormal liver enzymes were positively associated with cardiometabolic comorbidities in patients with MASLD ( P for trend < 0.001). After follow‐up, patients with MASLD had a 9%–29% higher risk of all‐cause, cardiovascular‐related, or diabetes‐related mortality. In the groups with MASLD and elevated and normal liver enzyme levels, the multivariate‐adjusted hazard ratios for cardiovascular deaths were 1.14 (1.05–1.25) and 1.10 (1.03–1.17), respectively, and those for diabetes deaths were 1.42 (1.05–1.93) and 1.24 (0.98–1.57), respectively, compared with those in the non‐MASLD group ( P for trend < 0.001).

Discussion

Individuals with MASLD and elevated liver enzyme levels exhibited significantly higher risks of all‐cause and cardiometabolic deaths and should be monitored and given consultation on cardiometabolic modifications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHumansMaleFemaleMiddle AgedPrevalenceAdultFatty LiverLiverCardiometabolic Risk FactorsTime FactorsAgedMetabolic DiseasesRisk FactorsAlanine Transaminase

Stichwörter der Autor:innen

long‐term risknonalcoholic fatty liver diseasenoncommunicable diseases

Substanzen

Alanine Transaminase

Autor:innen und Institutionen

  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Advanced Therapeutics Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Gastroenterology, Chang-Gung Memorial Hospital, Kaohsiung, Taiwan.

ORCID-Profile: Jee-Fu Huang, Sheng-Nan Lu, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Ming-Lung Yu, Mei-Hsuan Lee

Förderung

  • Ministry of Science and Technology, Taipei, Taiwan
  • NYCU-KMU Joint Research Project
  • Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung
  • National Health Research Institute, Chunan, Taiwan

Zitieren

APA

Chen, Y. T., Chen, T. I., Yin, S. C., Huang, C. W., Huang, J. F., Lu, S. N., Yeh, M. L., Huang, C. F., Dai, C. Y., Chen, Y. W., Chuang, W. L., Yu, M. L., & Lee, M. H. (2024). Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16592

Vancouver

Chen YT, Chen TI, Yin SC, Huang CW, Huang JF, Lu SN, et al. Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16592

BibTeX
@article{Chen2024,
  author = {Chen, Yi-Ting and Chen, Tzu-I and Yin, Szu-Ching and Huang, Chia-Wei and Huang, Jee-Fu and Lu, Sheng-Nan and Yeh, Ming-Lun and Huang, Chung-Feng and Dai, Chia-Yen and Chen, Yu-Wei and Chuang, Wan-Long and Yu, Ming-Lung and Lee, Mei-Hsuan},
  title = {Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16592}
}
Kostenlos starten →